Search

Your search keyword '"Lai, Ming‐Wei"' showing total 581 results
Start Over Author "Lai, Ming‐Wei"
581 results on '"Lai, Ming‐Wei"'

16. Occult Hepatitis B Virus Infection in Immunized Infants Born to Untreated and Tenofovir-Treated Highly Viremic Mothers

Author

MK, Shyu, HL, Hwa, YN, Su, JC, Shih, KH, Chao, YC, Chiu, CJ, Liu, TH, Su, DS, Chen, SM, Chen, CC, Lin, PY, Lin, WR, Yang, JJ, Hu, CK, Yang, YK, Chang, KH, Chen, HH, Lin, YH, Lin, HJ, Chen, HS, Pan, BH, Lau, CL, Lee, PJ, Cheng, YL, Chang, HY, Chiueh, TH, Wang, JJ, Hsu, LM, Lo, CL, Hsieh, SW, Cheng, MS, Tsai, BQ, She, FS, Peng, YC, Lin, CP, Chen, JP, Huang, CY, Yeung, Hsu, Hong-Yuan, Chen, Huey-Ling, Wu, Jia-Feng, Ni, Yen-Hsuan, Chang, Kai-Chi, Chiang, Cheng-Lun, Lee, Chien-Nan, Zhao, Lu-Lu, Lai, Ming-Wei, Mu, Shu-Chi, Wen, Wan-Hsin, Lin, Lung-Huang, and Chang, Mei-Hwei

Published
2021
Full Text
View/download PDF

22. Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate

Author

Shyu, M.K., Hwa, H.L., Su, Y.N., Shih, J.C., Chao, K.H., Chiu, Y.C., Chang, K.C., Liu, C.J., Su, T.H., Chen, D.S., Chen, S.M., Lin, C.C., Lin, P.Y., Yang, W.R., Hu, J.J., Yang, C.K., Chang, Y.K., Chen, K.H., Lin, H.H., Lin, Y.H., Chen, H.J., Pan, H.S., Lau, B.H., Lee, C.L., Cheng, P.J., Chang, Y.L., Chiueh, H.Y., Wang, T.H., Hsu, J.J., Lo, L.M., Hsieh, C.L., Cheng, S.W., Tsai, M.S., Lin, L.H., She, B.Q., Peng, F.S., Lin, Y.C., Chen, C.P., Huang, J.P., Yeung, C.Y., Wen, Wan-Hsin, Chen, Huey-Ling, Shih, Tiffany Ting-Fang, Wu, Jia-Feng, Ni, Yen-Hsuan, Lee, Chien-Nan, Zhao, Lu-Lu, Lai, Ming-Wei, Mu, Shu-Chi, Tung, Yi-Ching, Hsu, Hong-Yuan, and Chang, Mei-Hwei

Published
2020
Full Text
View/download PDF

23. Upper Gastrointestinal Involvement in Crohn's Disease as an Independent Predictor of New-Onset Strictures: Insights from a Extensive Retrospective Cohort Analysis

Author

Hsu, Wei-Chun, primary, Chen, Chien-Ming, additional, Kuo, Chia-Jung, additional, Tsou, Yung-Kuan, additional, Yeh, Pai-Jui, additional, Lai, Ming‑Wei, additional, Wu, Ren-Chin, additional, Chiu, Cheng-Tang, additional, Su, Ming‑Yao, additional, Pan, Yu-Bin, additional, and Le, Puo-Hsien, additional

Published
2024
Full Text
View/download PDF

24. Risk factors of mortality following hospital admission for Crohn's disease: A cohort study at a tertiary referral center in Taiwan

Author

Huang, Po‐Han, primary, Lin, Wey‐Ran, additional, Le, Puo‐Hsien, additional, Lin, Cheng‐Yu, additional, Chen, Chun‐Wei, additional, Wu, Ren‐Chin, additional, Hsu, Jun‐Te, additional, Tsai, Wen‐Sy, additional, Lai, Ming‐Wei, additional, Hsieh, Sen‐Yung, additional, Su, Ming‐Yao, additional, Chiu, Cheng‐Tang, additional, and Kuo, Chia‐Jung, additional

Published
2024
Full Text
View/download PDF

34. An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection.

Author

Chien, Hao, Chu, Yu-De, Hsu, Yi-Ping, Yeh, Chau-Ting, Lai, Ming-Wei, Chang, Ming-Ling, Lim, Siew-Na, Chen, Chun-Wei, and Lin, Wey-Ran

Subjects
ADJUVANT chemotherapy, COLORECTAL cancer, GENOME-wide association studies, BREAST, CANCER prognosis, TREATMENT effectiveness
Abstract

Colorectal cancer (CRC) is a global health concern, necessitating adjuvant chemotherapy post-curative surgery to mitigate recurrence and enhance survival, particularly in intermediate-stage patients. However, existing therapeutic disparities highlight the need for biomarker-guided adjuvant chemotherapy to achieve better CRC inhibition. This study explores the molecular mechanisms underlying the inhibition of CRC through a genome-wide association study (GWAS) focused on 5-fluorouracil (5-FU)-based adjuvant therapy in intermediate-stage CRC patients, a domain previously unexplored. We retrospectively included 226 intermediate-stage CRC patients undergoing surgical resection followed by 5-FU-based adjuvant chemotherapy. The exploration cohort comprised 31 patients, and the validation cohort included 195 individuals. Genotyping was carried out using either Axiom Genome-Wide TWB 2.0 Array Plate-based or polymerase chain reaction-based methods on genomic DNA derived from collected tissue samples. Statistical analyses involved descriptive statistics, Kaplan–Meier analyses, and Cox proportional hazard analyses. From the GWAS, potential genetic predictors, GALNT14-rs62139523 and DNMBP-rs10786578 genotypes, of 5-FU-based adjuvant therapy following surgery in intermediate-stage CRC patients were identified. Validation in a larger cohort of 195 patients emphasized the predictive significance of GALNT14-rs62139523 genotypes, especially the "A/G" genotype, for improved overall and progression-free survival. This predictive association remained robust across various subgroups, with exceptions for specific demographic and clinical parameters such as age < 58 years old, CEA ≤ 2.5 ng/mL, tumor diameter > 44.0 mm, and tumor-free margin ≥ 50 mm. This study identifies that the GALNT14-rs62139523 "A/G" genotype modulates therapeutic outcomes, establishing it as a promising biomarker for predicting favorable responses to 5-FU-based adjuvant chemotherapy in intermediate-stage CRC patients, although further investigations are needed to detail these mechanisms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.

Author

Chen, Huey‐Ling, Lee, Chien‐Nan, Chang, Chin‐Hao, Lai, Ming‐Wei, Tsai, Ming‐Chieh, Mu, Shu‐Chi, Liu, Chun‐Jen, Shih, Jin‐Chung, Wen, Wan‐Hsin, Hu, Rui‐Ting, Huang, Chun‐Pin, Hu, Kuang‐Chun, Chen, Chie‐Pein, Lee, Chyi‐Long, Chien, Rong‐Nan, Chang, Kai‐Chi, Hsu, Hong‐Yuan, Lee, Chien‐Chang, Ni, Yen‐Hsuan, and Chang, Mei‐Hwei

Subjects
HEPATITIS B virus, TENOFOVIR, INFANTS, PREGNANCY, PREGNANT women
Abstract

Background: The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother‐to‐child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation. Methods: The maternal and infant outcomes were compared in multi‐centre trials of high viral load HBsAg/HBeAg+ pregnant women receiving TAF or TDF from the third trimester until 2 weeks postpartum with intensive follow‐ups. To explore the dynamic pre‐ and postpartum changes in ALT levels, we used a group‐based trajectory model for analysing data of 332 women from three prospective studies. Results: After treatment, the maternal HBV DNA levels significantly decreased from baseline to delivery: 7.87 ± 0.59 to 3.99 ± 1.07 Log10 IU/mL TAF (n = 78) and 8.30 ± 0.36 to 4.47 ± 0.86 Log10 IU/mL (TDF, n = 53), with viral load reductions of 3.87 versus 3.83 Log10 IU/mL. The HBsAg‐positive rates among 12‐month‐old infants were 1.28% (1/78) versus 1.82% (1/55) respectively (p = 1.00). Of the TAF or TDF‐treated mothers, 25.64% versus 16.98% experienced ALT > 2X ULN, and 11.54% versus 1.89% received extended antiviral treatment. Our model revealed four distinct ALT patterns: stable ALT (87.2%), moderate (8.0%) or marked (2.4%) postpartum flares, or prepartum elevations (2.4%). Conclusions: TAF effectively reduces mother‐to‐child HBV transmission, but prophylaxis failure still occurred in few cases. Postpartum ALT flares are common in women receiving TAF or TDF during pregnancy. Approximately 12.8% of mothers may require extended postpartum antiviral treatment. Clinical trial number: NCT03695029 (ClinicalTrials.gov). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Risk factors of mortality following hospital admission for Crohn'sdisease: A cohort study at a tertiary referral center in Taiwan

Author

Huang, Po‐Han, Lin, Wey‐Ran, Le, Puo‐Hsien, Lin, Cheng‐Yu, Chen, Chun‐Wei, Wu, Ren‐Chin, Hsu, Jun‐Te, Tsai, Wen‐Sy, Lai, Ming‐Wei, Hsieh, Sen‐Yung, Su, Ming‐Yao, Chiu, Cheng‐Tang, and Kuo, Chia‐Jung

Abstract

The prevalence and incidence of Crohn's disease (CD) in Asia is rising, and it is important to know the risk factors of mortality. In our study, CD patients diagnosed and treated in the Chang Gung Memorial Hospital Linkou branch were enrolled from January 1989 to October 2019. The collected data included age, sex, disease duration, location and behavior of the disease, biochemical parameters at admission, medication history, surgical history, and comorbidities. The mean age at diagnosis was 35.7 ± 16.1 years old and the male‐to‐female ratio was 2.4. The penetrating type of CD was the most common (41.3%) of disease behavior. The ileocolonic area is the most common location of disease involvement (79%). 7.7% of patients had low serum albumin levels (<3 g/dL). 16.8% of patients had hemoglobin levels less than 10 g/dL. Of the patients included, 4 died during the follow‐up period. Low serum albumin levels at admission (p= .0307) are an independent predictor for mortality. In conclusion, it is important in perioperative care, especially for CD patients with hypoalbuminemia.

Published
2024
Full Text
View/download PDF

49. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer

Author

Yang, Yao-Jong, Lo, Gin-Ho, Kong, Man-San, Wang, Po-Ming, Yang, Chi-Chieh, Chu, Chia-Hsiang, Lin, Lung-Huan, Chien, Rong-Nan, Lee, Tzong-Hsi, Yang, Kuo-Ching, Liao, Li-Ying, Mo, Lein-Ray, Liu, Jean-Dean, Yang, Tzeng-Huey, Lo, Ching-Chu, Tsai, Ming-Hung, Chou, Chang-Hua, Cheng, Yeong-Shan, Chang, Mei-Hwei, You, San-Lin, Chen, Chien-Jen, Liu, Chun-Jen, Lai, Ming-Wei, Wu, Tzee-Chung, Wu, Shu-Fen, Lee, Chuan-Mo, Yang, Sheng-Shun, Chu, Heng-Cheng, Wang, Tsang-Eng, Chen, Bor-Wen, Chuang, Wan-Long, Soon, Maw-Soan, Lin, Ching-Yih, Chiou, Shu-Ti, Kuo, Hsu-Sung, and Chen, Ding-Shinn

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results